Active Biotech AB (OSTO:ACTI) Research & Development: kr22.80 Mil (TTM As of Mar. 2026)


OSTO:ACTI Active Biotech AB OSTO:ACTI
28 GF Score
Price kr5.75
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB Research & Development?

Active Biotech AB OSTO:ACTI +2.31% 28 Research & Development is kr22.80 Mil as of Mar. 2026. GuruFocus rates OSTO:ACTI with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Active Biotech AB's Research & Development for the three months ended in Mar. 2026 was kr5.80 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr22.80 Mil.

Active Biotech AB  (OSTO:ACTI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Active Biotech AB Research & Development Related Terms

Active Biotech AB Research & Development Historical Data

* Premium members only.

The historical data trend for Active Biotech AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Active Biotech AB Research & Development Chart

Active Biotech AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.54 42.82 32.54 26.67 25.24

Active Biotech AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.20 7.60 3.30 6.10 5.80
OSTO:ACTI
28GF Score
Active Biotech AB OSTO:ACTI
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Active Biotech AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr22.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr22.80 Mil mean?
Active Biotech AB (OSTO:ACTI) has a Research & Development of kr22.80 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Active Biotech AB and its competitors.
Is Active Biotech AB's Research & Development too high?
Active Biotech AB's current Research & Development is kr22.80 Mil. Overall, Active Biotech AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's Research & Development compare to VRTX and REGN?
Active Biotech AB's Research & Development of kr22.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Active Biotech AB and its competitors. Active Biotech AB's current Research & Development is kr22.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Active Biotech AB (OSTO:ACTI) has a current Research & Development of kr22.80 Mil. The current Research & Development is kr22.80 Mil. Active Biotech AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Active Biotech AB (OSTO:ACTI), the current Research & Development is kr22.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Active Biotech AB Business Description

Other Exchanges 0GQU:UKBTP:Germany
Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
28GF Score

Get the complete analysis for OSTO:ACTI

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr5.75
Price